L.J. Altfest & Co’s Arcutis Biotherapeutics ARQT Stock Holding History

L.J. Altfest & Co’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,830	Closed	-$373K	–	334
2025 Q4	$373K	Sell	12,830 -3,882	-23%	-$99.4K	0.04%	259
2025 Q3	$315K	Buy	+16,712	New	+$264K	0.04%	279
2025 Q1	–	Sell	-14,455	Closed	-$201K	–	326
2024 Q4	$201K	Buy	14,455 +47	+0.3%	+$515	0.03%	313
2024 Q3	$134K	Buy	+14,408	New	+$142K	0.02%	325

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

L.J. Altfest & Co's ARQT Position: Q1 2026 in Review

L.J. Altfest & Co sold out of Arcutis Biotherapeutics (ARQT) in Q1 2026, closing a stake of 12,830 shares — an estimated $373K sold.

L.J. Altfest & Co first reported a position in ARQT in Q3 2024 and held it in 4 quarters. The position peaked at $373K in Q4 2025. 270 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

L.J. Altfest & Co reported no remaining Arcutis Biotherapeutics position as of Q1 2026 after selling out during the quarter.
L.J. Altfest & Co sold 12,830 Arcutis Biotherapeutics shares in Q1 2026, an estimated $373K.
L.J. Altfest & Co first reported a position in Arcutis Biotherapeutics in Q3 2024 and held it in 4 quarters.
L.J. Altfest & Co's Arcutis Biotherapeutics position peaked at $373K in Q4 2025.
270 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on L.J. Altfest & Co's 13F filing for Q1 2026, filed 28 Apr 2026.